and meta-analyses when evaluating the evidence on biomarkers.”—Esther Landhuis None
with blocked lysosomal proteolysis.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=2803
news story).—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=2799 Triplet Repeat
in SCA7 and HD as well.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=2798 Triplet Repeat
antibodies, Rowan noted.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=2797 Alzheimer's
is hosting a one-day conference on May 24.—Esther Landhuis None
with Esther Landhuis's unfolding coverage of the San Francisco conference and her now-complete coverage
the drill will penetrate the topic of synaptic pathophysiology in neurodegenerative disease.—Esther
the idea that the shared gene set “sits neatly between amyloid and tau,” Lovestone said.—Esther Landhuis.
tau isoforms that appear in the brain (see review by Souter and Lee, 2010).—Esther Landhuis.
of post-translational modifications and interacting proteins. For more on these developments, read Part 2.—Esther
these possible side effects, Tomita said.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=2778
with the Clinical Trials on Alzheimer’s Disease Conference, 3-5 November 2011 in San Diego.—Esther Landhuis.
in terms of recapitulating FTD phenotype,” Boxer told ARF.—Esther Landhuis. This is Part 2 of a three-part
about that, see Part 2 and Part 3.—Esther Landhuis. This is Part 1 of a three-part series. See also Part